Xenon Pharmaceuticals/$XENE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Ticker
$XENE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Burnaby, Canada
Employees
322
ISIN
CA98420N1050
Website
XENE Metrics
BasicAdvanced
$2.5B
-
-$3.22
1.22
-
Price and volume
Market cap
$2.5B
Beta
1.22
52-week high
$44.74
52-week low
$26.74
Average daily volume
1.3M
Financial strength
Current ratio
17.656
Quick ratio
17.43
Long term debt to equity
1.036
Total debt to equity
1.232
Profitability
EBITDA (TTM)
-290.362
Gross margin (TTM)
-2,931.25%
Net profit margin (TTM)
-3,352.61%
Operating margin (TTM)
-3,906.60%
Effective tax rate (TTM)
1.59%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-22.03%
Return on equity (TTM)
-31.60%
Valuation
Price to revenue (TTM)
339.771
Price to book
3.55
Price to tangible book (TTM)
3.55
Price to free cash flow (TTM)
-12.755
Free cash flow yield (TTM)
-7.84%
Free cash flow per share (TTM)
-255.58%
Growth
Earnings per share change (TTM)
19.15%
3-year revenue growth (CAGR)
-31.01%
10-year revenue growth (CAGR)
-12.15%
3-year earnings per share growth (CAGR)
27.27%
10-year earnings per share growth (CAGR)
19.64%
What the Analysts think about XENE
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
Bulls say / Bears say
Xenon Pharmaceuticals' lead candidate, azetukalner, is progressing through Phase 3 trials for focal onset seizures (FOS) and major depressive disorder (MDD), with topline data anticipated in the second half of 2025, potentially leading to regulatory approval and commercialization. (Xenon Pharmaceuticals Press Release)
The company's strong financial position, with cash and cash equivalents totaling $803.3 million as of September 30, 2024, provides a solid foundation to support ongoing and future clinical programs without immediate need for additional financing. (Xenon Pharmaceuticals Press Release)
Analyst firms such as Raymond James have issued an 'Outperform' rating for Xenon Pharmaceuticals, reflecting confidence in the company's clinical progress and potential market performance. (Investing.com)
The failure of the SCN8A Phase 2 clinical trial for focal-onset seizures raises concerns about the efficacy of Xenon's pipeline beyond azetukalner, potentially impacting future growth prospects. (Investing.com)
Despite a strong cash position, Xenon reported a net loss of $62.8 million for the quarter ended September 30, 2024, indicating ongoing financial challenges that may necessitate future capital raises. (Xenon Pharmaceuticals Press Release)
The biopharmaceutical industry is highly competitive, and Xenon's success is contingent upon the successful development and commercialization of its pipeline, which carries inherent risks and uncertainties. (Xenon Pharmaceuticals Press Release)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
XENE Financial Performance
Revenues and expenses
XENE Earnings Performance
Company profitability
XENE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $2.5B as of July 15, 2025.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of July 15, 2025.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.